Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know

Core Viewpoint - Intellia Therapeutics, Inc. (NTLA) has shown significant stock price appreciation of 72.1% over the past four weeks, with a mean price target of $33.46 indicating a potential upside of 63.7% from the current price of $20.44 [1] Price Targets and Analyst Estimates - The mean estimate consists of 24 short-term price targets with a standard deviation of $24.02, indicating variability among analysts. The lowest estimate is $8.00 (60.9% decline), while the highest is $106.00 (418.6% increase) [2] - Analysts' price targets can often mislead investors, as empirical research shows that these targets rarely indicate the actual price direction of a stock [7] - A low standard deviation in price targets suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Agreement - Strong agreement among analysts in revising earnings per share (EPS) estimates higher supports the expectation of an upside for NTLA, as trends in earnings estimate revisions correlate with near-term stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.1%, with one estimate moving higher and no negative revisions [12] - NTLA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating potential upside in the near term [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of NTLA's potential gains, the implied direction of price movement appears to be a useful guide [14]